Cardio Diagnostics Q2: Material Weakness, Nasdaq Delisting Risk, and $1.5M Loss on $5K Revenue
CDIO sits 85% above its 52-week low of $0.97 on light trading volume (0.1× avg).
Summary
Cardio Diagnostics reported a $1.5M Q2 loss on just $5,360 in revenue, disclosed a material weakness in financial controls, and warned that its Nasdaq listing is at risk under a proposed new rule. The company is surviving on dilutive ATM share sales and has only $5.6M in cash.
Key Events · Earnings and Guidance · CDIO
-
Material Weakness Disclosed
Management identified a material weakness in internal control over financial reporting due to inadequate segregation of duties, and concluded disclosure controls were not effective as of June 30, 2026.
-
Nasdaq Delisting Risk
A new SEC rule would require $5M minimum market value of listed securities; Cardio's MVLS was $4.9M on August 6, 2026, putting its Nasdaq listing in immediate jeopardy if the rule takes effect.
-
Q2 Financials: $1.5M Loss on $5K Revenue
Revenue was $5,360 for the quarter, down from $7,475 a year ago. Net loss was $1.5M, with operating cash burn of $2.9M for the first half of 2026.
-
Dilutive ATM Sales Fund Operations
The company sold 1,133,418 shares under its ATM program in H1 2026, raising $3.69M net. Cash at June 30 was $5.6M, and the company warns it will need additional capital to fund operations beyond 12 months.
Analysis · CDIO · Life Sciences
Cardio Diagnostics' Q2 2026 filing reveals a trifecta of red flags: a newly disclosed material weakness in internal controls, an explicit warning that its stock could be delisted under a proposed Nasdaq rule, and continued negligible revenue ($5,360) against a $1.5 million quarterly loss. The company burned $2.9 million in operations during the first half and relied entirely on ATM share sales to stay afloat, issuing 1.13 million shares for $3.69 million in net proceeds. With only $5.6 million in cash and a market value hovering near the $5 million delisting threshold, the company faces an existential liquidity and listing crisis. The material weakness — inadequate segregation of duties — compounds the risk, signaling that even basic financial controls are lacking. This is not a routine quarterly update; it is a distress signal that fundamentally alters the investment thesis.
At the time of this filing, CDIO was trading at $1.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.3M. The 52-week trading range was $0.97 to $7.91. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.